BACKGROUND: Because of the current epidemic of human papillomavirus (HPV)-related oropharyngeal cancer (OPC), a screening strategy is urgently needed. The presence of serum antibodies to HPV-16 early (E) antigens is associated with an increased risk for OPC. The purpose of this study was to evaluate the diagnostic accuracy of antibodies to a panel of HPV-16 E antigens in screening for OPC. METHODS: This case-control study included 378 patients with OPC, 153 patients with nonoropharyngeal head and neck cancer (non-OPC), and 782 healthy control subjects. The tumor HPV status was determined with p16 immunohistochemistry and HPV in situ hybridization. HPV-16 E antibody levels in serum were identified with an enzyme-linked immunosorbent assay. A trained binary logistic regression model based on the combination of all E antigens was predefined and applied to the data set. The sensitivity and specificity of the assay for distinguishing HPV-related OPC from controls were calculated. Logistic regression analysis was used to calculate odds ratios with 95% confidence intervals for the association of head and neck cancer with the antibody status. RESULTS: Of the 378 patients with OPC, 348 had p16-positive OPC. HPV-16 E antibody levels were significantly higher among patients with p16-positive OPC but not among patients with non-OPC or among controls. Serology showed high sensitivity and specificity for HPVrelated OPC (binary classifier: 83% sensitivity and 99% specificity for p16-positive OPC). CONCLUSIONS: A trained binary classification algorithm that incorporates information about multiple E antibodies has high sensitivity and specificity and may be advantageous for risk stratification in future screening trials. Cancer 2017;123:4886-94.
INTRODUCTION
Human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has now reached epidemic proportions in many areas of the world, and the incidence is increasing substantially every year. As a result, in the United States, the incidence of OPC in men is now greater than the incidence of cervical cancer in women, and it is expected to continue to increase over the next several decades in the United States and parts of Europe and Asia. [1] [2] [3] [4] [5] [6] Primary prevention of OPC through vaccination against HPV is possible; however, population-level effects will take decades to realize. If current incidence trends continue and no changes are made in screening or early detection, rates of HPV-related OPC are not expected to decrease until 2060. 2 It is currently not possible to detect precursor lesions for HPV-related OPC or even early-stage HPV-related OPC, and no effective screening paradigm exists. If early-stage disease could be detected, modern transoral surgical techniques would allow localized treatment of the tonsils or base of the tongue to reduce cancer morbidity and mortality; this is a hallmark of a successful screening program. In addition, if a group at high risk for HPV-related cancers were confirmed, strategies for HPV-related cancer prevention such as immune modulation could be explored.
Serum antibodies to HPV-16 early (E) antigens have emerged as promising biomarkers that could aid in identifying individuals at high risk for OPC who could then go on to further screening. The detection of these antibodies has been shown to be both a marker of increased risk for OPC and other HPV-related cancers and a prognostic marker for patients with OPC, and it is rare among individuals without known cancer. [7] [8] [9] [10] [11] [12] [13] In a previous study, 9 we showed that compared with seronegative patients, patients seropositive for HPV-16 E antibodies had approximately 250 times the risk for HPV-positive OPC. In the study reported here, we improved on our previous work by exploring the diagnostic accuracy of a panel of HPV-16 E antibodies for HPV-related OPC in a completely independent and much larger cohort of patients with more robust tumor HPV testing.
MATERIALS AND METHODS

Study Design and Participants
This case-control study included participants in a prospective molecular epidemiology study of head and neck cancer conducted at The University of Texas MD Anderson Cancer Center; they were recruited from February 2003 through January 2013. All patients with newly diagnosed, histologically confirmed, previously untreated squamous cell carcinoma of the head and neck (the included sites were the oral cavity, oropharynx, hypopharynx, and larynx) who had tumor p16 expression data available were included in the current analysis. Control subjects were healthy visitors to the institution with no previous history of cancer other than nonmelanoma skin cancer. Control subjects were frequency-matched by age (65 years) and sex to case subjects. None of the patients or control subjects included here were included in our previous studies of HPV serology. 9, 10 Written informed consent was obtained from all participants. At the time of recruitment, participants provided demographic and exposure information as well as blood samples for biological testing. For cases, this occurred before the initiation of treatment. Blood samples were collected with a standard protocol and were stored at -808C until use. The study was approved by the MD Anderson institutional review board. Tumor p16 expression was evaluated in paraffinembedded tumor tissue with IHC performed with the CINtec histology kit (Ventana Medical Systems, Tucson, Arizona) per our routine clinical practice. Tumor p16 expression is considered a valid surrogate marker for OPC tumor HPV status and is the marker used to determine the HPV status for OPC in the new American Joint Committee on Cancer staging system (8th edition) 14, 15 ; therefore, patients with OPC whose tumors exhibited positive p16 expression were considered to have HPVpositive tumors. HPV ISH was performed with the ISHcatalyzed signal-amplification method for biotinylated probes for HPV types 16, 18, 31, 33 , and 51 (Enzo, Farmingdale, New York).
HPV DNA Cloning and Expression
Plasmids containing HPV-16 genes 16 were expressed as C-terminal glutathione S-transferase (GST) fusion proteins with human HeLa cell lysate 17 (Thermo Scientific, Waltham, Massachusetts) per the manufacturer's instructions. The HPV-16 early protein 2 (E2) gene was expressed as N-and C-terminal fragments (NE2 and CE2, respectively) for optimal protein expression. 7 GST was expressed to serve as a negative control protein. All recombinant DNA research was performed according to the guidelines of the National Institutes of Health under institutional biologic safety review and approval.
Enzyme-Linked Immunosorbent Assay (ELISA)
ELISAs were performed at Arizona State University essentially as described 18 with modifications. 19 Protein was expressed from template complementary DNA and captured on 96-well plates coated with anti-GST antibodies (GE Healthcare, Piscataway, New Jersey). Sera were diluted (1:100) and blocked with Escherichia coli lysate and 0.2% milk/phosphate-buffered saline with Tween 20. Horseradish peroxidase-labeled, anti-human immunoglobulin G antibodies (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania) were added at 1:10,000 and were detected with the SuperSignal ELISA Femto chemiluminescent substrate (Thermo Scientific). Luminescence was detected as relative light units (RLUs) on a GloMax 96-microplate luminometer (Promega, Madison, Wisconsin) at 425 nm. To control for nonspecific and GST-specific antibodies, the ratio of RLUs for individual HPV-specific antibodies to RLUs for the control GST antigen was measured. Samples were analyzed simultaneously in duplicate, and investigators were blinded with respect to the case-control and HPV status of the samples. Quality-control measures were previously published. 9 
Statistical Analysis
Because few patients had tumors of the hypopharynx or larynx, patients with such tumors were grouped with patients with oral cavity tumors, and this group is hereafter referred to as patients with nonoropharyngeal head Serum Antibodies to HPV-16 Early Antigens/Dahlstrom et al Cancer December 15, 2017 and neck cancer (non-OPC). Patients with p16-positive and p16-negative OPC were analyzed separately because of the clinical significance of p16 expression in OPC. The analysis was repeated for patients concordant for p16-positive/HPV ISH-positive OPC. Patients with non-OPC were analyzed together, regardless of their p16/ISH status, because they were considered HPV-unrelated. Cutoff values for positivity were determined with 247 control subjects from a previous study who were not included in the current analysis. 9 The cutoff values were defined as 3 standard deviations from the mean RLU ratio for each individual antigen and were as follows: E1, 2.2; NE2, 2.4; CE2, 2.3; E4, 2.3; E5, 1.7; E6, 2.4; E7, 2.2; late protein1 (L1), 1.9; and L2, 1.9. A sample with an RLU ratio equal to or greater than the cutoff value was considered positive for that antigen.
A trained binary logistic regression classifier based on the combined RLU ratio of all E antigens 9, 20 was applied to the data set. The binary classifier was implemented in MATLAB R2014b. Our classifier was used to calculate the probability of being positive or negative for HPV-related OPC on the basis of the combination of the different levels of antibodies against these antigens. We applied the maximum likelihood estimation to fit the binary logistic regression to a training data set, and this resulted in the optimization of each of the weights in the logistic regression. The decision boundary for a binary logistic regression lies where the prediction probability is 0.5. 21 Therefore, we defined a probability of being positive for HPV-related OPC at 0.5. To evaluate the predictive power of our classifier, our trained model was applied to an independent data set. 20 Subsequently, our trained and validated binary logistic regression model was applied to the data set presented in this case-control study. A more detailed description of the classifier is included in the online supporting information.
The test's sensitivity, specificity, area under the curve, Cohen's j coefficient, and diagnostic accuracy were calculated to evaluate the ability of the assay to correctly classify p16-positive and p16-positive/HPV ISH-positive OPC. The diagnostic accuracy was calculated as the proportion of subjects correctly classified by the test in the total study population.
Significant differences between groups were determined with the chi-square test or Fisher's exact test for categorical variables and with the Student t test or MannWhitney test for continuous variables. McNemar's chisquare test was used to determine significant differences in sensitivity and specificity between the classifier and the individual antibodies. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated with logistic regression. The hierarchical backward elimination approach was used to select variables for inclusion in the multivariable models. Variables that were not significant at P < .05 by the Wald statistic were removed one by one, and a decision to include each variable was based on the likelihood ratio test. None of the tested interaction terms were significant, and they were, therefore, not included in the analysis. None of the variables included in the models violated the assumption of linearity. The HosmerLemeshow goodness-of-fit test was used to determine the overall model fit. The variables included were sex, smoking, and alcohol use for the model of non-OPC versus controls and smoking and alcohol use for the models of p16-positive OPC and p16-positive/ISH-positive OPC versus controls. Observations with missing values were dropped from the multivariable analysis.
Statistical significance was set at P < .05, and all tests were 2-sided. Stata 12.0 (StataCorp LP, College Station, Texas) was used for all statistical analyses. MATLAB and Stata scripts are available upon request. Table 1 (see online supporting information) show the distribution of antibody levels for 782 control subjects, 153 patients with non-OPC, 348 patients with p16-positive OPC, and 30 patients with p16-negative OPC included in this study. Compared with controls, patients with p16-positive OPC had significantly higher levels of all antibodies measured; there was no significant difference in antibody levels between control subjects and patients with non-OPC. The top 2 outliers for antibody levels among patients with non-OPC were 1 patient with an oral cavity tumor and 1 patient with a larynx tumor, both of whom had HPV-related (p16-positive and HPV ISH-positive) non-OPC, a rare entity. Although the median levels of E1, E2, and L2 were significantly higher among patients with p16-negative OPC versus controls, these results should be interpreted with caution because of the small sample size (Supporting Table 1 ). Only 2% of the controls and 5% of the patients with non-OPC were E6 and/or E7 antibody-positive, whereas 74% of the patients with p16-positive OPC and 76% of the patients with p16-positive/ISH-positive OPC were (Table 1) . With the binary classifier, 1% of the controls, 3% of the patients with non-OPC, 83% of the patients with p16-positive OPC, and 85% of the patients with p16-positive/ISH-positive OPC had positive results (Table 1) . We did not see a difference in seropositivity for the binary classifier when p16-positive OPC was stratified Original Article by stage (American Joint Committee on Cancer TNM staging, 7th ed.: 85% for I/II vs 83% for III/IV; P 5 1.0), although seropositive patients were more likely to present with T1 to T3 tumors and N2c to N3 disease (P 5 .06 and P 5 .05 [chi-square], respectively). Because of the low number of p16-positive OPC cases with stage I/II disease, we did not perform any further analyses to determine a possible association between seropositivity and stage at diagnosis.
RESULTS
Figure 1 and Supporting
Demographic and exposure characteristics of the study population are shown in Table 1 . Controls and patients with non-OPC had similarly low rates of positivity for the tested antibodies; patients with p16-positive OPC had much higher rates of positivity (Table 1) . Among the 66 patients with p16-positive, HPV ISH-negative OPC, 16 of the 21 tested (76%) had HPV-16 DNA identified in tumor tissue by polymerase chain reaction, whereas among the 22 patients with p16-positive, HPV ISH-negative non-OPC, only 2 of the 10 tested (20%) had HPV-16 DNA identified in tumor tissue (data not shown).
Evaluation of HPV-16 E Antibodies as a Potential Diagnostic Biomarker for HPV-Related OPC
The performance of HPV-16 E antibodies as a marker for HPV-related OPC is shown in Table 2 . Overall, the antibody assay performed well. The sensitivity of the binary classifier was 83%, and the specificity was 99%; this resulted in the correct classification of 94% of the individuals with p16-positive OPC. In comparison with individual antibodies, the binary classifier had superior sensitivity (P < .001 for all) and performed better with respect to specificity for E1, E5, and E6 and/or E7 (P < .001 for E1 and E5; P 5 .012 for E6 and/or E7; data not shown). The classifier performed equally well for p16-positive/ISHpositive OPC (sensitivity, 85%; diagnostic accuracy, 95%).
Association Between HPV-16 E Antibodies and Non-OPC and p16-Positive OPC The presence of antibodies significantly increased the risk for p16-positive OPC but not the risk for non-OPC L2 Figure 1 . RLU ratios for each antibody among controls, patients with non-OPC, and patients with p16-positive OPC. None of the non-OPC/control RLU ratios were significant at P < .05, and all of the p16-positive OPC/control RLU ratios were significant at P < .001. P values were calculated with the Mann-Whitney test. CE2 indicates E2 C-terminal fragment; E, early protein; L, late protein; NE2, E2 N-terminal fragment; non-OPC, nonoropharyngeal head and neck cancer; OPC, oropharyngeal cancer; RLU, relative light unit.
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December 15, 2017 (Table 3) . Specifically, the classifier showed the strongest association with HPV-related OPC (OR for p16-positive OPC, 453; 95% CI, 199-1030; OR for p16-positive/ ISH-positive OPC, 565; 95% CI, 239-1335). In contrast, none of the associations between antibody status and non-OPC were significant.
DISCUSSION
In this large case-control study, we found that patients with HPV-related OPC were significantly more likely than cancer-free controls to have HPV-16 E antibodies, and a trained binary classification algorithm had high sensitivity and specificity for HPV-related OPC. Antibody positivity among patients with non-OPC occurred at rates similar to those observed in controls. An association between seropositivity for HPV-16 E antibodies and HPV-related cancers, including OPC, has been observed in previous studies by our group and others. 8, 9, 12, 13, [22] [23] [24] According to data from the European Prospective Investigation Into Cancer and Nutrition cohort, which included 638 patients with head and neck cancer and 1599 control subjects, antibodies to E6 were Abbreviations: CE2, E2 C-terminal fragment; E, early protein; HPV, human papillomavirus; IQR, interquartile range; ISH, in situ hybridization; L, late protein; NE2, E2 N-terminal fragment; non-OPC, nonoropharyngeal head and neck cancer; OPC, oropharyngeal cancer; SD: standard deviation. a P values are for comparisons with controls. b This was a subset of p16-positive OPC cases that were also HPV ISH-positive; note that HPV ISH was unavailable for 11 p16-positive OPC cases. c Adjusted for unequal variances. d Fisher's exact test. e The binary classifier was based on a combination of antibodies that was based on a receiver operating characteristic analysis; 0.5 was considered positive.
present in fewer than 1% of controls and in 35% of OPC cases; furthermore, antibodies could be detected more than 10 years before diagnosis. 8 With the same multiplex assay, these results were validated in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, in which antibody levels were found to remain elevated and stable for up to 13 years before diagnosis. 12 Moreover, the 10-year cumulative incidence of OPC among seropositive individuals was 6.2% for men and 1.3% for women. 12 In a previous study of 256 OPC cases and 250 controls, we found that seropositivity for E2, E6, and/or E7 was associated with OPC risk (OR, 249.1; 95% CI, 99.3-624.9). 9 Our current results are consistent with these previous findings. In the current study of a separate and larger cohort with comprehensive tumor HPV classification, we applied a trained algorithm for the classification of HPV status based on our previous cohort and found that, in our current cohort, the classifier had a sensitivity and specificity of 83% and 99%, respectively, with an associated greater than 450-fold-increased risk for p16-positive OPC. The improved performance of the classifier over E6 and/or E7, which had a sensitivity of 74% and a specificity of 98%, supports the use of a multipanel assay for screening. Although our assay shows promise as a biomarker for the detection of HPV-related OPC in this case-control study, further studies are needed. Specifically, we need 1) to study the ability of the marker to identify cases before a clinical diagnosis in cohort studies, 2) to study the implementation of screening tools in those testing positive to determine detection and false-referral rates in prospective screening studies, and 3) to determine cost-effectiveness and reduction in the burden of cancer in the screened population. 25, 26 Consequently, we are using these data to support the design of a trial evaluating HPV-16 E antibody-based screening for OPC risk stratification in men in their 50s (a group with a high incidence of HPVrelated OPC) and evaluating novel imaging techniques for the early detection of OPC (ClinicalTrials.gov identifier NCT02897427).
p16 by IHC is an accepted surrogate marker for tumor HPV status for OPC but is a poor marker for tumor HPV status for non-OPC. [27] [28] [29] [30] Our results add to the evidence showing that although non-OPC tumors may overexpress p16, they are not driven by HPV. We found that although 31% of the patients with non-OPC had p16-positive tumors, the HPV-16 E antibody positivity rate for these patients more closely resembled the rates for controls and patients with p16-negative OPC than the rate for patients with p16-positive OPC. In fact, there was no significant difference in the antibody status between patients with p16-positive and p16-negative non-OPC, whereas there was a significant difference in the antibody status between patients with p16-positive non-OPC and p16-positive OPC (positivity for any E antigen: P 5 .601 and P < .001, respectively). With the trained binary classifier, 4 patients with non-OPC were classified as antibody-positive, and 3 of these patients had p16-positive tumors (2 also had HPV ISH-positive tumors) and may have had true HPV-related non-OPC. Our findings indicate that non-OPC tumors, including the majority of those that are p16-positive, are unlikely to be attributable to HPV; however, as reported in the literature, we cannot discount the possibility that a small fraction of non-OPC tumors may be related to HPV. [28] [29] [30] This work expands on a previous study by our group but is substantially different from that study. 9 In the work presented herein, we analyzed a completely different and larger cohort, we included patients with non-OPC to serve as an HPV-negative comparison group, and we used p16 IHC and HPV ISH in place of polymerase chain reaction to determine the HPV status. As in our previous work, the investigators performing the serology assay were blinded with respect to the case-control and HPV status. Finally, on the basis of our previous work, we applied a trained algorithm to predict HPV positivity based on combined antibody levels, and the use of this algorithm improved the specificity of the assay to 99%, a level of specificity necessary for targeted population-based screening of a (currently) low-incidence cancer.
The limitations of this study include the inability to isolate the effects of individual antibodies (because most seropositive subjects were positive for multiple antibodies) and the potential misclassification of tumor HPV status. Although we determined tumor HPV status of OPC by using p16 by IHC, a marker currently in use as a surrogate for HPV status of OPC in clinical trials as well as the 8th edition of the staging manual of the American Joint Committee on Cancer, 14, 15, [31] [32] [33] misclassification of the HPV status may have occurred. Our data suggest that this is unlikely to have occurred in more than a few cases. Of the 367 patients with OPC who had p16 and ISH data available, only 1% (n 5 4) had p16-negative, HPV ISH-positive tumors. Although 18% (n 5 66) had p16-positive, HPV ISH-negative tumors, the limited sensitivity of ISH makes it likely that most of these cases were truly HPVpositive. The large point estimates with wide CIs in the logistic regression analysis suggest that our study is biased because of sparse data due to the low number of seropositive controls. Nevertheless, our results indicate a strongly positive and clinically relevant association between seropositivity and the diagnosis of HPV-related OPC.
Antibodies to HPV-16 E antigens are a promising marker for HPV-related OPC, and we generated a sensitive and specific algorithm for classifying patients with respect to HPV-16 E antigen positivity. Such a classifier could be used to identify at-risk individuals who would benefit from further screening. Screening methods such as transoral optical imaging and neck ultrasonography are currently being investigated as noninvasive methods for detecting OPC at earlier stages, and they would allow earlier treatment to prevent significant morbidity and mortality. Whether HPV-16 E antibodies ultimately prove to be adequate for selecting at-risk populations for careful Original Article
